| 產品描述： | UPGL00004 是一種有效的谷氨酰胺酶 C (GAC) 抑制劑 (IC50=29 nM; Kd=27 nM)。UPGL00004 強烈抑制高度侵襲性三陰性乳腺癌細胞系的增殖。 |
| 靶點： |
IC50: 29 nM (Glutaminase C); Kd: 27 nM (Glutaminase C);Glutaminase |
| 體外研究： |
UPGL00004 inhibits MDA-MB-231, HS578T and TSE cells with IC50s of 70, 129, and 262 nM, respectively. |
| 體內研究： |
The combination of UPGL00004 (1 mg/kg body weight) and Bevacizumab (2.5 mg/kg body weight) via intraperitoneal injection completely prevent any detectable increase in tumor size in a triple-negative breast cancer patient-derived tumor graft model. |
| 參考文獻： |
1. Huang Q, et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem. 2018 Mar 9;293(10):3535-3545. |
| 溶解性： |
soluble in DMSO |
| 保存條件： |
-20°C |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.87 ml |
9.352 ml |
18.703 ml |
| 5 mM |
0.374 ml |
1.87 ml |
3.741 ml |
| 10 mM |
0.187 ml |
0.935 ml |
1.87 ml |
| 50 mM |
0.037 ml |
0.187 ml |
0.374 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京